We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

HORIBA Medical

HORIBA ABX designs, develops and distributes worldwide, in vitro diagnostic systems for biological analysis in medica... read more Featured Products: More products

Download Mobile App




New Hematology Analyzers Deliver Combined ESR and CBC/DIFF Results in 60 Seconds

By LabMedica International staff writers
Posted on 25 Jun 2024
Print article
Image: The new Yumizen H550E (autoloader), H500E CT (closed tube), and Yumizen H500E OT (open tube) (Photo courtesy of HORIBA)
Image: The new Yumizen H550E (autoloader), H500E CT (closed tube), and Yumizen H500E OT (open tube) (Photo courtesy of HORIBA)

HORIBA (Kyoto, Japan) has expanded its line of compact hematology analyzers by introducing new models that incorporate Erythrocyte Sedimentation Rate (ESR) measurement capabilities. The newly launched Yumizen H550E (autoloader), H500E CT (closed tube), and Yumizen H500E OT (open tube) now deliver combined results for complete blood count (CBC)/differential (DIFF) and ESR from whole blood in just 60 seconds. This integration provides a more comprehensive assessment of inflammatory diseases, adding significant value to the instruments' existing extensive functionalities.

The integration of ESR into its three new analyzers has been made possible through HORIBA's innovative CoRA (Correlated Rouleaux Analysis) technology. By combining CBC and 5-population white blood cell DIFF with rapid ESR, calibrated to the Westergren reference method, these compact analyzers can reduce both costs per test and turnaround times, while also saving laboratory space. Additionally, both the Yumizen H550E and H500E models feature enhanced connectivity for data management through HORIBA’s Yumizen P8000 middleware and Yumicare, a remote technical support tool that ensures secure connections to the instruments for monitoring workload, reagent consumption, quality control, and instrument alarms.

The evolution of the Yumizen H550 range has also seen the inclusion of i-DoubleDiff technologies, which utilize artificial intelligence (AI) to provide score flags for infectious diseases such as malaria and dengue fever. This feature enhances the diagnostic speed and expands the utility of the analyzers in diverse medical environments, including both advanced and resource-limited settings. DoubleDiff technology further supports the addition of Normal leucocyte count (Lymphocyte, Monocyte, Neutrophil, Eosinophil, Basophil) + Abnormal leucocyte count (IMG, IMM, IML, LIC, ALY). With just two reagents, this technology has expanded the analytical capabilities of the analyzers from 27 to 37 parameters, offering deeper insights and more comprehensive results, especially in oncology. Thanks to its advanced technologies, affordability, reliability, and simplicity, the Yumizen H550 range is well-suited for a variety of clinical settings, including critical care, oncology, infectious disease management, blood banks, satellite laboratories, and health centers.

“Building on the global success of our previous Yumizen H550 range, we have designed the new analyzers to meet the increasing demand for affordable, robust, and highly capable hematology analyzers with connectivity that are suitable for any lab environment,” said Arnaud Pradel, President, HORIBA ABX SAS. “It is one instrument with endless possibilities, and the capabilities of our Yumizen H550 range continue to grow to meet even more clinical lab needs.”

Related Links:
HORIBA

New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Dengue Virus Test
LINEAR Dengue-CHIK

Print article

Channels

Clinical Chemistry

view channel
Image: The proposed self-powered, millifluidic lab-on-a-chip device to determine blood conductivity (Photo courtesy of Advanced Materials/DOI: 10.1002/adma.202403568)

First-Ever Blood-Powered Chip Offers Real-Time Health Monitoring

Metabolic disorders such as diabetes and osteoporosis are rapidly increasing globally, especially in developing countries. Diagnosing these conditions generally requires blood tests; however, in remote... Read more

Molecular Diagnostics

view channel
Image: The U.S. FDA has granted marketing authorization for the Xpert HCV test together with the GeneXpert Xpress System (Photo courtesy of Cepheid)

First POC Hepatitis C RNA Test Enables Single-Visit Testing and Treatment

Hepatitis C, a liver infection caused by the hepatitis C virus (HCV), spreads through contact with the blood of an infected person. While some individuals may experience a short-term illness, over half... Read more

Industry

view channel
Image: For 46 years, Roche and Hitachi have collaborated to deliver innovative diagnostic solutions (Photo courtesy of Roche)

Roche and Hitachi High-Tech Extend 46-Year Partnership for Breakthroughs in Diagnostic Testing

Roche (Basel, Switzerland) and Hitachi High-Tech (Tokyo, Japan) have renewed their collaboration agreement, committing to a further 10 years of partnership. This extension brings together their long-standing... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.